Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

9.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
9.8K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.9K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

10.2K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
10.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

4.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
4.3K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

6.1K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
6.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL.

Blood advances·2026
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Blood neoplasia·2026

Related Experiment Video

Updated: Oct 13, 2025

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

244

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.

Andrew D Zelenetz1, Leo I Gordon2, Julie E Chang3

  • 1Memorial Sloan Kettering Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|November 15, 2021
PubMed
Summary
This summary is machine-generated.

Novel targeted therapies, including small molecule inhibitors and CAR T-cell therapy, offer new treatment options for relapsed/refractory B-cell non-Hodgkin lymphomas. These advancements are reflected in updated NCCN Guidelines for B-Cell Lymphomas.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.9K

Related Experiment Videos

Last Updated: Oct 13, 2025

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

244
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.9K

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Significant advancements in understanding B-cell non-Hodgkin lymphomas' molecular pathogenesis over the past decade.
  • Emergence of targeted therapies addressing specific molecular pathways and proteins involved in lymphoma development.

Purpose of the Study:

  • To highlight novel targeted therapy options for relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas.
  • To present updates to the NCCN Guidelines for B-Cell Lymphomas based on new therapeutic developments.

Main Methods:

  • Review of recent molecular and clinical research in B-cell non-Hodgkin lymphomas.
  • Inclusion of new targeted agents in NCCN Guidelines, including small molecule inhibitors and CAR T-cell therapy.

Main Results:

  • Identification of novel targeted therapies such as kinase inhibitors, antibody-drug conjugates, and protein-targeting small molecules (CD-19, EZH2, XPO-1).
  • Anti-CD19 CAR T-cell therapy approved for R/R diffuse large B-cell lymphoma and emerging for R/R follicular lymphoma and mantle cell lymphoma.

Conclusions:

  • New targeted therapies represent significant progress in treating R/R B-cell non-Hodgkin lymphomas.
  • Updated NCCN Guidelines incorporate these novel treatment strategies, offering improved options for patients with R/R disease.